C-H Heldin

639 total citations
8 papers, 543 citations indexed

About

C-H Heldin is a scholar working on Molecular Biology, Oncology and Surgery. According to data from OpenAlex, C-H Heldin has authored 8 papers receiving a total of 543 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Molecular Biology, 3 papers in Oncology and 2 papers in Surgery. Recurrent topics in C-H Heldin's work include Glycosylation and Glycoproteins Research (2 papers), Cell Adhesion Molecules Research (2 papers) and TGF-β signaling in diseases (2 papers). C-H Heldin is often cited by papers focused on Glycosylation and Glycoproteins Research (2 papers), Cell Adhesion Molecules Research (2 papers) and TGF-β signaling in diseases (2 papers). C-H Heldin collaborates with scholars based in Sweden, Belgium and Greece. C-H Heldin's co-authors include Thomas Sejersen, Maria Sjölund, Ulf Hedin, J Thyberg, Paraskevi Heldin, Helena Porsch, Achilleas D. Theocharis, Bengt Westermark, Monica Nistér and Sefanja Achterberg and has published in prestigious journals such as The Journal of Cell Biology, Oncogene and British Journal of Cancer.

In The Last Decade

C-H Heldin

8 papers receiving 534 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
C-H Heldin Sweden 8 339 136 127 100 65 8 543
Carl Henrik Heldin Sweden 5 275 0.8× 99 0.7× 100 0.8× 93 0.9× 27 0.4× 6 447
Yin Xu United States 11 600 1.8× 230 1.7× 169 1.3× 173 1.7× 82 1.3× 15 858
Romina Dossi Italy 10 453 1.3× 201 1.5× 103 0.8× 158 1.6× 70 1.1× 11 708
Uwe Dietz Germany 13 366 1.1× 95 0.7× 72 0.6× 123 1.2× 64 1.0× 16 702
Jürgen Adamkiewicz Germany 8 433 1.3× 117 0.9× 47 0.4× 109 1.1× 103 1.6× 12 549
Steven Song United States 6 327 1.0× 165 1.2× 53 0.4× 115 1.1× 79 1.2× 10 550
Terry Lipari United States 5 419 1.2× 159 1.2× 77 0.6× 69 0.7× 58 0.9× 5 686
Ana Llorens Spain 8 372 1.1× 226 1.7× 91 0.7× 138 1.4× 52 0.8× 13 557
Erica Lorenzon Switzerland 7 291 0.9× 104 0.8× 73 0.6× 114 1.1× 81 1.2× 8 468
Sofia Edlund Sweden 5 592 1.7× 182 1.3× 100 0.8× 88 0.9× 55 0.8× 5 737

Countries citing papers authored by C-H Heldin

Since Specialization
Citations

This map shows the geographic impact of C-H Heldin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by C-H Heldin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites C-H Heldin more than expected).

Fields of papers citing papers by C-H Heldin

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by C-H Heldin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by C-H Heldin. The network helps show where C-H Heldin may publish in the future.

Co-authorship network of co-authors of C-H Heldin

This figure shows the co-authorship network connecting the top 25 collaborators of C-H Heldin. A scholar is included among the top collaborators of C-H Heldin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with C-H Heldin. C-H Heldin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

8 of 8 papers shown
1.
Heldin, C-H, et al.. (2017). The deubiquitinating enzymes USP4 and USP17 target hyaluronan synthase 2 and differentially affect its function. Oncogenesis. 6(6). e348–e348. 27 indexed citations
2.
Caja, Laia, Kalliopi Tzavlaki, Tobias Bergström, et al.. (2013). Snail depletes the tumorigenic potential of glioblastoma. Oncogene. 32(47). 5409–5420. 60 indexed citations
3.
Porsch, Helena, et al.. (2012). Efficient TGFβ-induced epithelial–mesenchymal transition depends on hyaluronan synthase HAS2. Oncogene. 32(37). 4355–4365. 126 indexed citations
4.
Hägerstrand, Daniel, Göran Hesselager, Sefanja Achterberg, et al.. (2006). Characterization of an imatinib-sensitive subset of high-grade human glioma cultures. Oncogene. 25(35). 4913–4922. 78 indexed citations
5.
Yamada, Naoshi, Mitsuyasu Kato, Peter ten Dijke, et al.. (1996). Bone morphogenetic protein type IB receptor is progressively expressed in malignant glioma tumours. British Journal of Cancer. 73(5). 624–629. 31 indexed citations
6.
Heldin, N E, Kensuke Usuki, Jonas Bergh, Bengt Westermark, & C-H Heldin. (1993). Differential expression of platelet-derived endothelial cell growth factor/thymidine phosphorylase in human lung carcinoma cell lines. British Journal of Cancer. 68(4). 708–711. 25 indexed citations
7.
Heldin, C-H, Annet Hammacher, Monica Nistér, & Bengt Westermark. (1988). Structural and functional aspects of platelet-derived growth factor. British Journal of Cancer. 57(6). 591–593. 27 indexed citations
8.
Sjölund, Maria, Ulf Hedin, Thomas Sejersen, C-H Heldin, & J Thyberg. (1988). Arterial smooth muscle cells express platelet-derived growth factor (PDGF) A chain mRNA, secrete a PDGF-like mitogen, and bind exogenous PDGF in a phenotype- and growth state-dependent manner. The Journal of Cell Biology. 106(2). 403–413. 169 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026